Primary Bilateral Rhabdomyosarcoma of the Breast in a young female. Report of a case with unusual clinical presentation and review of the literature

Emily Alimia*, Cameron Volpe, Jacob Cunningham, Malina Mohtadi, Victoria DeTrolio, Bishoy Mark Joseph, Nastaran Biriji, and Mohamed Aziz

Department of Pathology, American University of the Caribbean School of Medicine, 1 University Drive at Jordan Road Cupecoy

Abstract
Cancer of the breast is the most common cancer among women. Rhabdomyosarcoma (RMS) of the breast is a rare sarcoma that is often diagnosed late. Only 5% of breast tumors are of non-epithelial origin, and only 0.2% of RMS originate in the breast.

Optimal treatment of breast rhabdomyosarcoma is not standardized yet. RMS can present a serious diagnostic challenge due to its resemblance to benign tumors of the breast in imaging studies leading to late diagnosis and unfavorable prognosis. Little is known about standard treatment of breast rhabdomyosarcoma. The 5-year survival rate for primary breast rhabdomyosarcoma is about 43%. We present a case of Primary Bilateral Rhabdomyosarcoma of the Breast in a young female with unusual clinical presentation with a review of the literature.

Keywords: Rhabdomyosarcoma, Breast, Bilateral, Benign, Malignant; Non-epithelial

Introduction
Rhabdomyosarcoma (RMS) is a rare soft tissue malignancy that is derived from cells that typically form striated muscle tissue. It is the most common soft tissue malignancy in children and adolescents, frequently involving the head, neck, orbital cavity, genitourinary system, and extremities. RMS can be broken down into subclassifications which include embryonal commonly involving the orbit, botryoid RMS commonly involving the bladder and vagina, anaplastic RMS associated with Li-Fraumeni syndrome, and alveolar RMS often involving extremities. In rare instances, RMS can originate from the breast.

Breast masses presenting in adolescent and young adult females are commonly benign such as fibroadenoma and fibrocystic changes. Due to the frequent presence of benign breast tumors, malignant masses may be easily overlooked. An extremely rare form of breast cancer is primary breast rhabdomyosarcoma, making up only 0.2% of cases. Although the alveolar subtype of RMS typically involves the extremities, it also contributes to the majority of primary breast RMS cases. According to Bayramoglu, only 25 cases of primary breast RMS in the pediatric population have been recorded between the years 1985 and 2017, exemplifying the rarity of this malignancy.

This case discusses primary bilateral RMS of the breast in an 18-year-old female. Due to the rare occurrence of this form of breast cancer, it is often diagnosed late and very little is known on how to effectively treat it. The 5-year survival rate for primary breast RMS is only 43%, making this a critical case report.

Case Presentation
An 18-year-old female presented to the breast clinic complaining of bilateral breast masses, which she noticed a few months earlier. The patient sought medical attention due to enlargement of the masses. Physical examination revealed no lymphadenopathy and the masses measured 4.2x3.6 (right) & 3.4x2.8 (left). She had no significant medical history or specific risk factors. The patient had no family history of breast cancer. Her father had a history of color cancer and her mother has a history of atypical endometrial hyperplasia.

An ultrasound was performed, which showed inhomogeneous, hypoechoic oval masses with well-defined margins, suggestive of a benign tumor. This was followed by a fine needle aspiration (FNA) and core biopsy from both masses of right and left breasts. There was round, oval and polygonal to elongated cells with occasional dispersed individual cells and many cells containing amphophilic cytoplasm with dense nuclear chromatin and irregular nuclear membranes (Figure 1A-B-C). The results were suggestive of a malignant neoplasm with "small blue cell" features, consistent with neuroendocrine tumor with differential diagnosis including lymphoma and sarcoma. A high suspicion of lymphoma rendered a bone marrow biopsy, which revealed
malignant cells with the same features as the breast masses (Figure 1D) Immunohistochemistry (IHC) studies revealed positivity for Desmin (Figure 1E), Myogenin (Figure 1F), Myoglobin, BCL-2, and CAM 5.2 (dot-like pattern) and negative reaction for Cytokeratin AE1/AE3, HMB-45, BREST-2, ER, PR, Cycline-D1, BCL-6, CD99, Synaptophysin and chromogranin. Additionally, fluorescence in situ hybridization (FISH) detected N-myc (MYCN) oncogene amplification. All of these results and findings were consistent with alveolar rhabdomyosarcoma. Total body imaging work up showed no evidence of malignancy elsewhere; therefore, the breast tumors were consistent with primary bilateral rhabdomyosarcoma of the breast.

After the exclusion of metastatic origin, a bilateral mastectomy with partial removal of the pectoralis muscle was performed. The pectoralis muscle under the breast deep fascia was not involved by Rhabdomyosarcoma, which ruled out possible origin from the chest muscles under the breast and confirmed the primary origin of the tumor. Post-operative chemotherapy treatment was given, including eight cycles of second-line chemotherapy with vincristine, dactinomycin, and endoxan. Additionally, the patient received radiation therapy due to the presence of tumor cells that were in close proximity to the deep fascia.

Following chemotherapy and radiation treatment the patient was free of tumor and had no recurrence of metastasis for thirteen months. After thirteen months, the patient began showing GI and pulmonary symptoms with metastasis to the abdominal cavity, lung, and bone. Due to the metastasis, another round of chemotherapy was given. The patient expired five weeks later.

Discussion
Cancer of the breast is the most common cancer among women. Among all breast cancer diagnoses, nonepithelial origin account for less than 5% of all breast neoplasms. Breast sarcomas are often unilateral, well-defined, painless and firm, with lymph node involvement being rare. Most of these tumors increase rapidly in size and grow to be larger than epithelial breast tumors. Though there are clinical distinguishing factors, it is not possible to determine breast cancer cell of origin based on clinical presentation alone. Early findings of a breast sarcoma may be clinically and radiologically similar to those of benign origin, causing them to be frequently diagnosed later in an advanced stage. Tissue biopsy with immunohistochemistry confirmation is a must to make an accurate diagnosis. Proper origin and diagnosis of non-epithelial tumors is required to determine optimal treatment, which differs from tumors of epithelial origin. Due to the aggressive behavior and poor prognosis of these tumors, complete mastectomy followed by chemotherapy and possible irradiation is the treatment of choice to obtain adequate negative margins.

Rhabdomyosarcoma of the breast is extremely rare, representing 0.2% of diagnosed breast cancers. Rhabdomyosarcoma is thought to arise from immature mesenchymal cells that are committed to skeletal muscle lineage, that is why these tumors can also arise in tissues in which striated muscle is not normally found, such as the breast. Classification of a tumor as RMS requires identification of skeletal muscle lineage features: rhabdomyoblasts and cross striations. RMS

Figure 1 Pathological examination of breast masses and bone marrow biopsy.
1A: Breast mass, fine needle aspiration smear cytology showing malignant small blue round cell tumor (DQ stain x60).
1B: Uninvolved breast tissue (right) infiltrated by small blue round cell tumor (left) (H&E stain x20).
1C: High power view of breast mass showing round, oval and polygonal to elongated tumor cells with occasional dispersed individual cells with dense nuclear chromatin and irregular nuclear membranes (H&E stain x60).
1D: Bone marrow biopsy showing infiltration by small blue round cell tumor (H&E stain x20).
1E: Tumor cells positive for Desmin.
1F: Tumor cells positive for Myogenin.
must be confirmed by positive staining for desmin, myogenin, and myoglobin. Heterologous rhabdomyosarcomatous differentiation, such as malignant phyllodes tumors, and metaplastic breast carcinomas should be excluded before making the final diagnosis of RMS.15-17

RMS tumors measuring >5 cm is sensitive to radiotherapy; however, radiotherapy may increase the risk of alveolar rhabdomyosarcoma.15-17 The 5-year survival rate for primary breast rhabdomyosarcoma is 43%.10

It is postulated that rhabdomyosarcoma can be either myogenic or non-myogenic. Myogenic RMS may be due to a subset of early muscle forming cells, the satellite cells. Non-myogenic RMS may be due to mesenchymal progenitor cells which are committed not only to striated muscle differentiation, but also to produce connective tissue. It is hypothesized that such non-myogenic cells may circulate in many different organs and may give rise to RMS in uncommon sites such as the breast in our case. Myogenin positive staining tumors are more associated with the alveolar type of RMS compared to embryonal RMS and are thought to have a poorer prognosis.

Mammography at the age of 40 is the most effective screening technique. Until recently, breast self-examination (BSE) has been found to also increase survival rates.15-17 However, with recent recommendations, most medical organizations don’t recommend routine breast self-exams as a part of breast cancer screening. That’s because breast self-exams haven’t been shown to be effective in detecting cancer or improving survival for women who have breast cancer. Still, doctors believe there is value in women being familiar with their own breasts, so they understand what’s normal and promptly report changes.19

We hope that this report raises awareness of what remains an unmet need in the definitive diagnosis and management of various breast malignancies. Furthermore, that the continued investigation drives further development of efficacious diagnosis and safe treatments for improving patient outcomes.

Acknowledgment

Special thanks to Aimee Lombard, Kyle Coombes, and Amanda Kuruvilla, MD candidates, American University of the Caribbean for their assistance in reviewing the final manuscript.

References